Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 4:46 pm Sale | 2023-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY | Perceptive Advisors LLC | 4,024,400 3.500% | -1,254,562 (-23.77%) | Filing History |
| 2024-02-14 4:05 pm Sale | 2023-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY | COMMODORE CAPITAL LP | 0 0.000% | -5,738,500 (Position Closed) | Filing History |
| 2024-02-14 12:50 pm Purchase | 2023-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY | JANUS HENDERSON GROUP PLC JHG | 6,103,797 5.400% | 6,103,797 (New Position) | Filing History |
| 2024-02-14 09:09 am Purchase | 2023-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY | AVORO CAPITAL ADVISORS LLC | 16,337,739 9.990% | 3,537,739 (+27.64%) | Filing History |
| 2024-02-13 5:02 pm Purchase | 2023-12-29 | 13G | CymaBay Therapeutics, Inc. CBAY | The Vanguard Group | 6,306,149 5.560% | 2,879,138 (+84.01%) | Filing History |
| 2024-02-13 4:27 pm Sale | 2023-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY | TCG Crossover GP I LLC | 0 0.000% | -5,905,400 (Position Closed) | Filing History |
| 2024-01-25 1:48 pm Purchase | 2023-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY | BlackRock Inc. BLK | 9,610,239 8.500% | 7,662,206 (+393.33%) | Filing History |
| 2023-09-22 4:30 pm Purchase | 2023-09-12 | 13G | CymaBay Therapeutics, Inc. CBAY | RA CAPITAL MANAGEMENT L.P. | 6,940,000 6.200% | 6,940,000 (New Position) | Filing History |
| 2023-09-11 4:45 pm Purchase | 2023-08-30 | 13G | CymaBay Therapeutics, Inc. CBAY | ADAGE CAPITAL PARTNERS GP L.L.C. | 3,685,625 3.760% | 1,525,475 (+70.62%) | Filing History |
| 2023-03-10 2:04 pm Purchase | 2023-03-03 | 13G | CymaBay Therapeutics, Inc. CBAY | Perceptive Advisors LLC | 5,278,962 5.600% | 5,278,962 (New Position) | Filing History |
| 2023-02-14 4:06 pm Purchase | 2022-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY | COMMODORE CAPITAL LP | 5,738,500 6.800% | 318,604 (+5.88%) | Filing History |
| 2023-02-14 2:23 pm Purchase | 2022-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY | TCG Crossover GP I LLC | 5,905,400 6.200% | 5,905,400 (New Position) | Filing History |
| 2022-07-08 4:57 pm Sale | 2022-06-30 | 13G | CymaBay Therapeutics, Inc. CBAY | BlackRock Inc. BLK | 1,948,033 2.300% | -3,376,095 (-63.41%) | Filing History |
| 2022-02-14 4:22 pm Sale | 2021-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY | Boxer Capital LLC | 0 0.000% | -4,000,000 (Position Closed) | Filing History |
| 2022-02-14 4:08 pm Purchase | 2021-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY | COMMODORE CAPITAL LP | 5,419,896 7.800% | 1,890,431 (+53.56%) | Filing History |
| 2022-02-11 10:03 am Purchase | 2021-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY | AVORO CAPITAL ADVISORS LLC | 12,800,000 14.700% | 2,500,000 (+24.27%) | Filing History |
| 2022-02-01 5:08 pm Sale | 2021-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY | BlackRock Inc. BLK | 5,324,128 6.300% | -62,116 (-1.15%) | Filing History |
| 2021-11-29 1:00 pm Purchase | 2021-11-22 | 13G | CymaBay Therapeutics, Inc. CBAY | TCG Crossover Management LLC | 5,905,400 7.000% | 5,905,400 (New Position) | Filing History |
| 2021-07-12 2:44 pm Purchase | 2021-06-30 | 13G | CymaBay Therapeutics, Inc. CBAY | COMMODORE CAPITAL LP | 3,529,465 5.100% | 3,529,465 (New Position) | Filing History |
| 2021-02-16 4:04 pm Sale | 2020-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY | D. E. Shaw & Co., L.P. | 1,260,749 1.800% | -2,188,863 (-63.45%) | Filing History |